Glenmark Pharmaceuticals Inc., USA is recalling 147,168 bottles of Pravastatin Sodium (80mg) tablets because the product failed dissolution testing. This means the tablets may not dissolve properly or release the active medication into the body as required. The recall affects 90-count and 500-count bottles of this cholesterol-lowering medication that were distributed nationwide throughout the United States.
If the tablets do not dissolve correctly, the medication may not be effectively absorbed into the bloodstream, potentially making the treatment less effective at lowering cholesterol. No reports of injuries or adverse events were mentioned in the recall notice.
You have 2 options:

Label, Glenmark Potassium Chloride Extended Release 750mg Capsules, 100 count

Label, Glenmark Potassium Chloride Extended Release 750mg Capsules, 500 count
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท FDA Press Release ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.